Humoral immunity in the Friend retrovirus infection model

Immunologic Research

Volumn 55, Issue 1-3, 2013, Pages 249-260

  Halemano, Kalani ^a   Harper, Michael S ^a   Guo, Kejun ^a   Li, Sam X ^a   Heilman, Karl J ^a   Barrett, Bradley S ^a   Santiago, Mario L ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

APOBEC3; Friend retrovirus; HIV; Neutralizing antibodies; Rfv3; Vaccines

Indexed keywords

ADENOVIRUS VECTOR; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; B CELL ACTIVATING FACTOR RECEPTOR; LIVE VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; RECOVERY FROM FRIEND VIRUS 3; UNCLASSIFIED DRUG; VIF PROTEIN;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; CELLULAR IMMUNITY; DISEASE MODEL; FRIEND LEUKEMIA VIRUS; FRIEND RETROVIRUS; FRIEND RETROVIRUS INFECTION; GENETIC CROSS; GENETIC MANIPULATION; HISTOCOMPATIBILITY COMPLEX; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; NONHUMAN; PASSIVE IMMUNIZATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROVIRUS; RETROVIRUS INFECTION; SPLEEN FOCUS FORMING VIRUS; VIRUS LIKE AGENT; VIRUS PARTICLE; VIRUS REPLICATION;

ANIMALS; DISEASE MODELS, ANIMAL; FRIEND MURINE LEUKEMIA VIRUS; HUMANS; IMMUNITY, HUMORAL; RETROVIRIDAE INFECTIONS;

EID: 84876741953     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-012-8370-y     Document Type: Article

References (102)

1. Shedlock DJ, Silvestri G, Weiner DB. Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nat Rev Immunol. 2009;9(10):717-28.
2. Zhang JX, Diehl GE, Littman DR. Relief of preintegration inhibition and characterization of additional blocks for HIV replication in primary mouse T cells. PLoS ONE. 2008;3(4):e2035.
3. Denton PW, Garcia JV. Novel humanized murine models for HIV research. Curr HIV/AIDS Rep. 2009;6(1):13-9.
4. Chesebro B, Miyazawa M, Britt WJ. Host genetic control of spontaneous and induced immunity to Friend murine retrovirus infection. Annu Rev Immunol. 1990;8:477-99.
5. Hasenkrug KJ, Chesebro B. Immunity to retroviral infection: the Friend virus model. PNAS USA. 1997;94(15):7811-6.
6. Miyazawa M, Tsuji-Kawahara S, Kanari Y. Host genetic factors that control immune responses to retrovirus infections. Vaccine. 2008;26(24):2981-96.
7. Li JP, D'Andrea AD, Lodish HF, Baltimore D. Activation of cell growth by binding of friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor. Nature. 1990;343(6260):762-4.
8. Persons DA, Paulson RF, Loyd MR, Herley MT, Bodner SM, Bernstein A, et al. Fv2 encodes a truncated form of the Stk receptor tyrosine kinase. Nat Genet. 1999;23(2):159-65.
9. Nishigaki K, Hanson C, Jelacic T, Thompson D, Ruscetti S. Friend spleen focus-forming virus transforms rodent fibroblasts in cooperation with a short form of the receptor tyrosine kinase Stk. PNAS USA. 2005;102(43):15488-93.
10. Finkelstein LD, Ney PA, Liu QP, Paulson RF, Correll PH. Sf-Stk kinase activity and the Grb2 binding site are required for Epo-independent growth of primary erythroblasts infected with Friend virus. Oncogene. 2002;21(22):3562-70.
11. Moreau-Gachelin F, Tavitian A, Tambourin P. Spi-1 is a putative oncogene in virally induced murine erythroleukaemias. Nature. 1988;331(6153):277-80.
12. Munroe DG, Peacock JW, Benchimol S. Inactivation of the cellular p53 gene is a common feature of Friend virus-induced erythroleukemia: relationship of inactivation to dominant transforming alleles. Mol Cell Biol. 1990;10(7):3307-13.
13. + T-cell responses by coinfection with lactate dehydrogenase-elevating virus. J Virol. 2008;82(1):408-18.
14. Li K, Schuler T, Chen Z, Glass GE, Childs JE, Plagemann PG. Isolation of lactate dehydrogenase-elevating viruses from wild house mice and their biological and molecular characterization. Virus Res. 2000;67(2):153-62.
15. Ammann CG, Messer RJ, Peterson KE, Hasenkrug KJ. Lactate dehydrogenase-elevating virus induces systemic lymphocyte activation via TLR7-dependent IFNalpha responses by plasmacytoid dendritic cells. PLoS ONE. 2009;4(7):e6105.
16. Gerlach N, Schimmer S, Weiss S, Kalinke U, Dittmer U. Effects of type I interferons on Friend retrovirus infection. J Virol. 2006;80(7):3438-44.
17. Marques R, Antunes I, Eksmond U, Stoye J, Hasenkrug K, Kassiotis G. B lymphocyte activation by coinfection prevents immune control of friend virus infection. J Immunol. 2008;181(5):3432-40.
18. + T cell response. J Virol. 2011;85(2):1151-5.
19. Riley V. Enzymatic determination of transmissible replicating factors associated with mouse tumors. Ann N Y Acad Sci. 1963;100:762-90.
20. Ebert PS, Chirigos MA, Fields LA, Ellsworth PA. Plasma lactate dehydrogenase and spleen heme biosynthetic activity following Friend and Rauscher leukemia virus infections. Life Sci. 1967;6(18):1963-71.
21. Hasenkrug KJ, Dittmer U. The role of CD4 and CD8 T cells in recovery and protection from retroviral infection: lessons from the Friend virus model. Virology. 2000;272(2):244-9.
22. Hasenkrug KJ, Dittmer U. Immune control and prevention of chronic Friend retrovirus infection. Front Biosci. 2007;12:1544-51.
23. Forster F, Medalia O, Zauberman N, Baumeister W, Fass D. Retrovirus envelope protein complex structure in situ studied by cryo-electron tomography. PNAS USA. 2005;102(13):4729-34.
24. Zhu P, Liu J, Bess J Jr, Chertova E, Lifson JD, Grise H, et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature. 2006;441(7095):847-52.
25. Chesebro B, Wehrly K. Identification of a non-H-2 gene (Rfv-3) influencing recovery from viremia and leukemia induced by Friend virus complex. PNAS USA. 1979;76(1):425-9.
26. Santiago ML, Montano M, Benitez R, Messer RJ, Yonemoto W, Chesebro B, et al. Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science. 2008;321(5894):1343-6.
27. Friend C. Cell-free transmission in adult Swiss mice of a disease having the character of a leukemia. J Exp Med. 1957;105(4):307-18.
28. Lilly F. Susceptibility to two strains of Friend leukemia virus in mice. Science. 1967;155(761):461-2.
29. Lilly F. Fv-2: identification and location of a second gene governing the spleen focus response to Friend leukemia virus in mice. J Natl Cancer Inst. 1970;45(1):163-9.
30. Lilly F. The effect of histocompatibility-2 type on response to friend leukemia virus in mice. J Exp Med. 1968;127(3):465-73.
31. Chesebro B, Wehrly K, Stimpfling J. Host genetic control of recovery from Friend leukemia virus-induced splenomegaly: mapping of a gene within the major histocompatability complex. J Exp Med. 1974;140(6):1457-67.
32. Chesebro B, Wehrly K. Rfv-1 and Rfv-2, two H-2-associated genes that influence recovery from Friend leukemia virus-induced splenomegaly. J Immunol. 1978;120(4):1081-5.
33. Doig D, Chesebro B. Anti-Friend virus antibody is associated with recovery from viremia and loss of viral leukemia cell-surface antigens in leukemic mice. Identification of Rfv-3 as a gene locus influencing antibody production. J Exp Med. 1979;150(1):10-9.
34. Hasenkrug KJ, Valenzuela A, Letts VA, Nishio J, Chesebro B, Frankel WN. Chromosome mapping of Rfv3, a host resistance gene to Friend murine retrovirus. J Virol. 1995;69(4):2617-20.
35. Super HJ, Hasenkrug KJ, Simmons S, Brooks DM, Konzek R, Sarge KD, et al. Fine mapping of the friend retrovirus resistance gene, Rfv3, on mouse chromosome 15. J Virol. 1999;73(9):7848-52.
36. Kanari Y, Clerici M, Abe H, Kawabata H, Trabattoni D, Caputo SL, et al. Genotypes at chromosome 22q12-13 are associated with HIV-1-exposed but uninfected status in Italians. AIDS. 2005;19(10):1015-24.
37. Waterston RH, Lindblad-Toh K, Birney E, Rogers J, Abril JF, Agarwal P, et al. Initial sequencing and comparative analysis of the mouse genome. Nature. 2002;420(6915):520-62.
38. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002;418(6898):646-50.
39. Santiago ML, Smith DS, Barrett BS, Montano M, Benitez RL, Pelanda R, et al. Persistent Friend virus replication and disease in Apobec3-deficient mice expressing functional B-cell-activating factor receptor. J Virol. 2011;85(1):189-99.
40. Smith DS, Guo K, Barrett BS, Heilman KJ, Evans LH, Hasenkrug KJ, et al. Noninfectious retrovirus particles drive the Apobec3/Rfv3 dependent neutralizing antibody response. PLoS Pathog. 2011;7(10):e1002284.
41. Tsuji-Kawahara S, Chikaishi T, Takeda E, Kato M, Kinoshita S, Kajiwara E, et al. Persistence of viremia and production of neutralizing antibodies differentially regulated by polymorphic APOBEC3 and BAFF-R loci in Friend virus-infected mice. J Virol. 2010;84(12):6082-95.
42. Abudu A, Takaori-Kondo A, Izumi T, Shirakawa K, Kobayashi M, Sasada A, et al. Murine retrovirus escapes from murine APOBEC3 via two distinct novel mechanisms. Curr Biol. 2006;16(15):1565-70.
43. Takeda E, Tsuji-Kawahara S, Sakamoto M, Langlois MA, Neuberger MS, Rada C, et al. Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo. J Virol. 2008;82(22):10998-1008.
44. Browne EP, Littman DR. Species-specific restriction of Apobec3-mediated hypermutation. J Virol. 2008;82(3):1305-13.
45. Sanville B, Dolan MA, Wollenberg K, Yan Y, Martin C, Yeung ML, et al. Adaptive evolution of Mus Apobec3 includes retroviral insertion and positive selection at two clusters of residues flanking the substrate groove. PLoS Pathog. 2010;6:e1000974.
46. Li J, Hakata Y, Takeda E, Liu Q, Iwatani Y, Kozak CA, et al. Two genetic determinants acquired late in Mus evolution regulate the inclusion of exon 5, which alters mouse APOBEC3 translation efficiency. PLoS Pathog. 2012;8(1):e1002478.
47. Okeoma CM, Petersen J, Ross SR. Expression of murine APOBEC3 alleles in different mouse strains and their effect on mouse mammary tumor virus infection. J Virol. 2009;83(7):3029-38.
48. Langlois MA, Kemmerich K, Rada C, Neuberger MS. The AKV murine leukemia virus is restricted and hypermutated by mouse APOBEC3. J Virol. 2009;83(22):11550-9.
49. Kolokithas A, Rosenke K, Malik F, Hendrick D, Swanson L, Santiago ML, et al. The glycosylated Gag protein of a murine leukemia virus inhibits the antiretroviral function of APOBEC3. J Virol. 2010;84(20):10933-6.
50. Kozak CA, Chakraborti A. Single amino acid changes in the murine leukemia virus capsid protein gene define the target of Fv1 resistance. Virology. 1996;225(2):300-5.
51. Casey RE. Mouse strain-specific splicing of Apobec3. MSc Thesis, Worcester Polytechnic Institute. 2006: http://www.wpi.edu/Pubs/ETD/Available/ etd-082206-113216/unrestricted/Casey.pdf.
52. Lassen KG, Wissing S, Lobritz MA, Santiago M, Greene WC. Identification of two APOBEC3F splice variants displaying HIV-1 antiviral activity and contrasting sensitivity to Vif. J Biol Chem. 2010;285(38):29326-35.
53. Biasin M, Piacentini L, Lo Caputo S, Kanari Y, Magri G, Trabattoni D et al. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. J Inf Dis. 2007;195(7):960-4.
54. Sui Y, Zhu Q, Gagnon S, Dzutsev A, Terabe M, Vaccari M, et al. Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. PNAS. 2010;107(21):9843-8.
55. Santiago ML, Benitez RL, Montano M, Hasenkrug KJ, Greene WC. Innate retroviral restriction by Apobec3 promotes antibody affinity maturation in vivo. J Immunol. 2010;185(2):1114-23.
56. Conticello SG, Thomas CJ, Petersen-Mahrt SK, Neuberger MS. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol Biol Evol. 2005;22(2):367-77.
57. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000;102(5):553-63.
58. Okeoma CM, Lovsin N, Peterlin BM, Ross SR. APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature. 2007;445(7130):927-30.
59. Low A, Okeoma CM, Lovsin N, de las Heras M, Taylor TH, Peterlin BM et al. Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene. Virology. 2009;385(2):455-63.
60. + T cells and gamma interferon in protection of mice against retrovirus-induced immunosuppression. J Virol. 2002;76(1):450-4.
61. Voltersvik P, Albrektsen G, Ulvestad E, Dyrhol-Riise AM, Sorensen B, Asjo B. Changes in immunoglobulin isotypes and immunoglobulin G (IgG) subclasses during highly active antiretroviral therapy: anti-p24 IgG1 closely parallels the biphasic decline in plasma viremia. J Acquir Immune Defic Syndr. 2003;34(4):358-67.
62. Morris L, Binley JM, Clas BA, Bonhoeffer S, Astill TP, Kost R, et al. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med. 1998;188(2):233-45.
63. Binley JM, Trkola A, Ketas T, Schiller D, Clas B, Little S, et al. The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection. J Inf Dis. 2000;182(3):945-9.
64. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell. 2003;114(1):21-31.
65. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10(11):787-96.
66. Browne EP, Littman DR. Myd88 is required for an antibody response to retroviral infection. PLoS Pathog. 2009;5(2):e1000298.
67. Browne EP. Toll-like receptor 7 controls the anti-retroviral germinal center response. PLoS Pathog. 2011;7(10):e1002293.
68. Kane M, Case LK, Wang C, Yurkovetskiy L, Dikiy S, Golovkina TV. Innate immune sensing of retroviral infection via Toll-like receptor 7 occurs upon viral entry. Immunity. 2011;35(1):135-45.
69. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477(7365):466-70.
70. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. NEJM. 2009;361(23):2209-20.
71. Ackerman ME, Dugast AS, Alter G. Emerging concepts on the role of innate immunity in the prevention and control of HIV infection. Ann Rev Med. 2012;63:113-30.
72. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012;482(7383):89-93.
73. Chesebro B, Wehrly K, Cloyd M, Britt W, Portis J, Collins J, et al. Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: Friend-specific and FMR-specific antigens. Virology. 1981;112(1):131-44.
74. Britt WJ, Chesebro B. Use of monoclonal anti-gp70 antibodies to mimic the effects of the Rfv-3 gene in mice with Friend virus-induced leukemia. J Immunol. 1983;130(5):2363-7.
75. Hasenkrug KJ, Brooks DM, Chesebro B. Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness. PNAS. 1995;92(23):10492-5.
76. Messer RJ, Dittmer U, Peterson KE, Hasenkrug KJ. Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection. PNAS USA. 2004;101(33):12260-5.
77. Sala A, Gresser I, Chassoux D, Maury C, Santodonato L, Eid P, et al. Inhibition of Friend leukemia cell visceral metastases by a new monoclonal antibody and role of the immune system of the host in its action. Cancer Res. 1992;52(10):2880-9.
78. Friend C. Immunological relationships of a filterable agent causing a leukemia in adult mice. I. The neutralization of infectivity by specific antiserum. J Exp Med. 1959;109(2):217-28.
79. Chesebro B, Wehrly K. Studies on the role of the host immune response in recovery from Friend virus leukemia. I. Antiviral and antileukemia cell antibodies. J Exp Med. 1976;143(1):73-84.
80. Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, Kalyanaraman R, et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol. 2002;76(17):8875-89.
81. Pantophlet R, Wang M, Aguilar-Sino RO, Burton DR. The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regions. J Virol. 2009;83(4):1649-59.
82. Ishihara C, Miyazawa M, Nishio J, Chesebro B. Induction of protective immunity to Friend murine leukemia virus in genetic nonresponders to virus envelope protein. J Immunol. 1991;146(11):3958-63.
83. Dittmer U, Brooks DM, Hasenkrug KJ. Characterization of a live-attenuated retroviral vaccine demonstrates protection via immune mechanisms. J Virol. 1998;72(8):6554-8.
84. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med. 2009;15(1):34-41.
85. Earl PL, Moss B, Morrison RP, Wehrly K, Nishio J, Chesebro B. T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science. 1986;234(4777):728-31.
86. Ishihara C, Miyazawa M, Nishio J, Azuma I, Chesebro B. Use of low toxicity adjuvants and killed virus to induce protective immunity against the Friend murine leukaemia retrovirus-induced disease. Vaccine. 1992;10(5):353-6.
87. Schlecht-Louf G, Renard M, Mangeney M, Letzelter C, Richaud A, Ducos B, et al. Retroviral infection in vivo requires an immune escape virulence factor encrypted in the envelope protein of oncoretroviruses. PNAS USA. 2010;107(8):3782-7.
88. Hunsmann G, Moennig V, Schafer W. Properties of mouse leukemia viruses. IX. Active and passive immunization of mice against Friend leukemia with isolated viral GP71 glycoprotein and its corresponding antiserum. Virology. 1975;66(1):327-9.
89. Hunsmann G, Schneider J, Schulz A. Immunoprevention of Friend virus-induced erythroleukemia by vaccination with viral envelope glycoprotein complexes. Virology. 1981;113(2):602-12.
90. Morrison RP, Earl PL, Nishio J, Lodmell DL, Moss B, Chesebro B. Different H-2 subregions influence immunization against retrovirus and immunosuppression. Nature. 1987;329(6141):729-32.
91. Miyazawa M, Nishio J, Chesebro B. Genetic control of T cell responsiveness to the Friend murine leukemia virus envelope antigen. Identification of class II loci of the H-2 as immune response genes. J Exp Med. 1988;168(5):1587-605.
92. Hasenkrug KJ, Brooks DM, Nishio J, Chesebro B. Differing T-cell requirements for recombinant retrovirus vaccines. J Virol. 1996;70(1):368-72.
93. Miyazawa M, Nishio J, Chesebro B. Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene. J Virol. 1992;66(7):4497-507.
94. McElrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity. 2010;33(4):542-54.
95. Bayer W, Schimmer S, Hoffmann D, Dittmer U, Wildner O. Evaluation of the Friend Virus model for the development of improved adenovirus-vectored anti-retroviral vaccination strategies. Vaccine. 2008;26(5):716-26.
96. Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol. 2003;77(11):6305-13.
97. Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature. 2006;441(7090):239-43.
98. Bayer W, Lietz R, Ontikatze T, Johrden L, Tenbusch M, Nabi G, et al. Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes. Retrovirology. 2011;8:75.
99. Best S, Le Tissier P, Towers G, Stoye JP. Positional cloning of the mouse retrovirus restriction gene Fv1. Nature. 1996;382(6594):826-9.
100. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 1992;258(5090):1938-41.
101. Schmitt K, Hill MS, Ruiz A, Culley N, Pinson DM, Wong SW, et al. Mutations in the highly conserved SLQYLA motif of Vif in a simian-human immunodeficiency virus result in a less pathogenic virus and are associated with G-to-A mutations in the viral genome. Virology. 2009;383(2):362-72.
102. Tong T, Crooks ET, Osawa K, Binley JM. HIV-1 virus-like particles bearing pure Env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes. J Virol. 2012;86(7):3574-87.